华北制药 (600812)

North China Pharmaceutical Co., Ltd.

ASH

Tags

DeepSeekSSE 580 IndexGeneric DrugsInnovative DrugsBroker Heavy PositionsFertilizer ConceptPharmaceutical ManufacturingPharmaceuticals and HealthcareSynthetic BiologyGene ConceptBackdoor ListingsBiological VaccinesVitaminsHepatitis ConceptMargin Trading and Securities LendingChina Securities Finance and Central Huijin HoldingsXiong'an New Area医药生物Chemical Pharmaceuticals

K-Line Chart

No K-line data available

Company NameNorth China Pharmaceutical Co., Ltd.
Listing Date1994-01-14
Issue Price4RMB
Registered Capital171573.03710k RMB
Legal RepresentativeWang Lixin
Registered AddressNo. 388 Heping East Road, Shijiazhuang City, Hebei Province
IndustryChemical Pharmaceuticals
Main BusinessEngaged in the research and development, production, and sales of pharmaceutical products.
Company ProfileNorth China Pharmaceutical Co., Ltd. (hereinafter referred to as the Company or North China Pharmaceutical) is one of China's chemical pharmaceutical enterprises. Its predecessor, North China Pharmaceutical Factory, was a key construction project during China's First Five-Year Plan. Established in 1953 and put into operation in 1958, it ended China's reliance on imports of penicillin and streptomycin, making significant contributions to alleviating the shortage of medicine in China. In August 1992, with North China Pharmaceutical Factory as the sponsor, all its production and operational assets were injected, and shares were privately placed to internal employees to establish the joint-stock company. On January 14, 1994, the Company was officially listed on the Shanghai Stock Exchange (Stock Code: 600812, Stock Abbreviation: "North China Pharmaceutical"). In June 2009, approved by the Hebei Provincial Party Committee and Provincial Government, Jizhong Energy Group Co., Ltd. (hereinafter referred to as Jizhong Energy Group) implemented an asset restructuring of North China Pharmaceutical Group Co., Ltd. (formerly North China Pharmaceutical Factory, hereinafter referred to as Huayao Group), making Jizhong Energy the Company's indirect controlling shareholder. In 2012 and 2014, the Company conducted two private placements of a total of 602,227,171 A-shares to Jizhong Energy. Upon completion of the issuance, Jizhong Energy directly held 36.93% of the Company's equity, becoming its largest shareholder.

Stock Details

1. Key Indicators

  • Total Shares(W): 171573.04
  • Circulating A-Shares(W): 171573.04
  • Earnings Per Share(RMB): 0.0920
  • Net Assets Per Share(RMB): 3.2087
  • Operating Revenue(W RMB): 748482.86
  • Total Profit(W RMB): 28721.56
  • **Net Profit Attributable to Parent(W RMB) **: 15850.40
  • Net Profit Growth Rate(%): 54.69
  • Weighted Return on Equity(%): 2.8980
  • Operating Cash Flow Per Share(RMB): 0.3860
  • Undistributed Profit Per Share(RMB): -0.2466
  • Capital Reserve Per Share(RMB): 2.2555

2. Main Business

The main business covers:

  • Research, development, production and sales of pharmaceutical products

3. Company Basic Information

  • Company Name: North China Pharmaceutical Co., Ltd.
  • Listing Date: 1994-01-14
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 388 Heping East Road, Shijiazhuang City, Hebei Province
  • Website: https://www.ncpc.com/
  • Company Profile: The company's predecessor was North China Pharmaceutical Factory. In August 1992, it began restructuring into a joint-stock company, converting the original company's net assets into 491.7791 million state-owned shares. After the initial public offering from August 1992 to October 1993, the total number of shares at the time of listing was 660 million shares; 21.608598 million internal employee shares were listed for trading on September 22, 1994.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Jizhong Energy Co., Ltd. General Legal Person 41308.05 24.08
2 North China Pharmaceutical Group Co., Ltd. General Legal Person 34147.16 19.90
3 Jizhong Energy Group Co., Ltd. General Legal Person 18914.67 11.02
4 Central Huijin Asset Management Co., Ltd. Special Legal Person 5491.66 3.20
5 Hong Kong Securities Clearing Company Ltd. Northbound Funds 2005.31 1.17
6 Caida Securities Co., Ltd. Securities Company 1320.00 0.77
7 Southern China Securities 1000 ETF Fund 784.47 0.46
8 ChinaAMC China Securities 1000 ETF Fund 466.25 0.27

5. Concept Sectors

  • Biological Vaccines
  • Xiongan New Area
  • Gene Concept
  • Vitamins
  • Generic Drugs
  • Fertilizer Concept
  • Hepatitis Concept
  • Innovative Drugs
  • Synthetic Biology
  • DeepSeek

Remarks

  • Data update date: 2025-10-24
  • Data source: Public market information